Printer Friendly

XOMA UPDATES FDA REVIEW STATUS OF E5

 XOMA UPDATES FDA REVIEW STATUS OF E5
 BERKELEY, Calif., June 4 /PRNewswire/ -- XOMA Corp.


(NASDAQ, NMS: XOMA) today announced that is has been notified that the Food and Drug Administration (FDA) has completed its review of the company's two multicenter, randomized, placebo-controlled studies of its E5 anti-endotoxin monoclonal antibody. In April, FDA informed XOMA that the results of the first study were not sufficient to demonstrate the efficacy of E5. Unexpectedly, FDA now has advised XOMA that the agency's review of the two studies has led it to conclude that additional clinical testing may be warranted. However, no preclinical, manufacturing/control, or safety concerns were raised by FDA. In addition, FDA officials have agreed to meet with XOMA in the next week to discuss options for the ongoing review of E5.
 -0- 6/4/92
 /CONTACT: Carol D. DeGuzman of XOMA, 510-644-1170/
 (XOMA) CO: XOMA ST: California IN: MTC SU:


RM-DG -- SF004 -- 7044 06/04/92 12:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 4, 1992
Words:159
Previous Article:DIAGNOSTEK ANNOUNCES FINANCIAL RESULTS
Next Article:BLM TO ELIMINATE CLEARCUTTING AS MAIN HARVEST METHOD UNDER NEW INITIATIVE
Topics:


Related Articles
XOMA ANNOUNCES FDA REVIEW OF FIRST E5(R) MULTICENTER STUDY COMPLETED AND EUROPEAN PATENT ALLOWABILITY
FDA REVIEW OF XOMA'S E5(R) PRODUCT IS ACTIVE; COMPANY BELIEVES MARKET OVERREACTED
FDA REVIEW OF XOMA'S E5(R) PRODUCT IS ACTIVE; COMPANY BELIEVES MARKET OVERREACTED
XOMA COMMENTS ON FDA REVIEW OF E5
XOMA ANNOUNCES NEW STRATEGIC FOCUS AND RESTRUCTURING
XOMA REPORTS 1992 THIRD QUARTER FINANCIAL RESULTS
MENDELL RESIGNS, CASTELLO ASSUMES CHAIRMAN ROLE AT XOMA
XOMA REPORTS 1993 FIRST QUARTER FINANCIAL RESULTS
XOMA ANNOUNCES NEW E5 CLINICAL TRIAL
Lexicon Genetics and XOMA Establish Collaboration for Antibody Drug Development and Commercialization.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters